These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 25503729)
1. Effects of hydration in rats and mice with polycystic kidney disease. Hopp K; Wang X; Ye H; Irazabal MV; Harris PC; Torres VE Am J Physiol Renal Physiol; 2015 Feb; 308(3):F261-6. PubMed ID: 25503729 [TBL] [Abstract][Full Text] [Related]
2. Role of vasopressin antagonists. Torres VE Clin J Am Soc Nephrol; 2008 Jul; 3(4):1212-8. PubMed ID: 18434616 [TBL] [Abstract][Full Text] [Related]
3. Increased salt intake does not worsen the progression of renal cystic disease in high water-loaded PCK rats. Nagao S; Kugita M; Kumamoto K; Yoshimura A; Nishii K; Yamaguchi T PLoS One; 2019; 14(3):e0207461. PubMed ID: 30870430 [TBL] [Abstract][Full Text] [Related]
4. Raising serum uric acid with a uricase inhibitor worsens PKD in rat and mouse models. Chaudhary A; He Z; Atwood DJ; Miyazaki M; Oto OA; Davidoff A; Edelstein CL Am J Physiol Renal Physiol; 2024 Jun; 326(6):F1004-F1015. PubMed ID: 38634129 [TBL] [Abstract][Full Text] [Related]
5. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. Nagao S; Nishii K; Katsuyama M; Kurahashi H; Marunouchi T; Takahashi H; Wallace DP J Am Soc Nephrol; 2006 Aug; 17(8):2220-7. PubMed ID: 16807403 [TBL] [Abstract][Full Text] [Related]
6. Increased water intake reduces long-term renal and cardiovascular disease progression in experimental polycystic kidney disease. Sagar PS; Zhang J; Luciuk M; Mannix C; Wong ATY; Rangan GK PLoS One; 2019; 14(1):e0209186. PubMed ID: 30601830 [TBL] [Abstract][Full Text] [Related]
7. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease. Wang X; Harris PC; Somlo S; Batlle D; Torres VE Nephrol Dial Transplant; 2009 Feb; 24(2):526-34. PubMed ID: 18826972 [TBL] [Abstract][Full Text] [Related]
8. Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease. Di Mise A; Wang X; Ye H; Pellegrini L; Torres VE; Valenti G FASEB J; 2021 Oct; 35(10):e21874. PubMed ID: 34486176 [TBL] [Abstract][Full Text] [Related]
10. Insignificant effect of secretin in rodent models of polycystic kidney and liver disease. Wang X; Ye H; Ward CJ; Chu JY; Masyuk TV; Larusso NF; Harris PC; Chow BK; Torres VE Am J Physiol Renal Physiol; 2012 Oct; 303(7):F1089-98. PubMed ID: 22811488 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Gattone VH; Wang X; Harris PC; Torres VE Nat Med; 2003 Oct; 9(10):1323-6. PubMed ID: 14502283 [TBL] [Abstract][Full Text] [Related]
12. Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease. Wang X; Jiang L; Thao K; Sussman CR; LaBranche T; Palmer M; Harris PC; McKnight GS; Hoeflich KP; Schalm S; Torres VE J Am Soc Nephrol; 2022 Jun; 33(6):1087-1104. PubMed ID: 35236775 [TBL] [Abstract][Full Text] [Related]
13. Effect of a Vasopressin V2 Receptor Antagonist on Polycystic Kidney Disease Development in a Rat Model. Wang X; Constans MM; Chebib FT; Torres VE; Pellegrini L Am J Nephrol; 2019; 49(6):487-493. PubMed ID: 31117065 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. Wang X; Gattone V; Harris PC; Torres VE J Am Soc Nephrol; 2005 Apr; 16(4):846-51. PubMed ID: 15728778 [TBL] [Abstract][Full Text] [Related]
15. Modulation of Polycystic Kidney Disease Severity by Phosphodiesterase 1 and 3 Subfamilies. Ye H; Wang X; Sussman CR; Hopp K; Irazabal MV; Bakeberg JL; LaRiviere WB; Manganiello VC; Vorhees CV; Zhao H; Harris PC; van Deursen J; Ward CJ; Torres VE J Am Soc Nephrol; 2016 May; 27(5):1312-20. PubMed ID: 26374610 [TBL] [Abstract][Full Text] [Related]
16. Accuracy and processing time of kidney volume measurement methods in rodents polycystic kidney disease models: superiority of semiautomated kidney segmentation. Doss MC; Mullen S; Roye R; Zhou J; Chumley P; Mrug E; Wallace DP; Qian F; Harris PC; Yoder BK; Kim H; Mrug M Am J Physiol Renal Physiol; 2023 Apr; 324(4):F423-F430. PubMed ID: 36794756 [TBL] [Abstract][Full Text] [Related]
17. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Bouby N; Bachmann S; Bichet D; Bankir L Am J Physiol; 1990 Apr; 258(4 Pt 2):F973-9. PubMed ID: 2184677 [TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats. Torres VE; Sweeney WE; Wang X; Qian Q; Harris PC; Frost P; Avner ED Kidney Int; 2004 Nov; 66(5):1766-73. PubMed ID: 15496147 [TBL] [Abstract][Full Text] [Related]
19. P2Y2 receptor mRNA and protein expression is altered in inner medullas of hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. Kishore BK; Krane CM; Miller RL; Shi H; Zhang P; Hemmert A; Sun R; Nelson RD Am J Physiol Renal Physiol; 2005 Jun; 288(6):F1164-72. PubMed ID: 15687250 [TBL] [Abstract][Full Text] [Related]
20. Vasopressin directly regulates cyst growth in polycystic kidney disease. Wang X; Wu Y; Ward CJ; Harris PC; Torres VE J Am Soc Nephrol; 2008 Jan; 19(1):102-8. PubMed ID: 18032793 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]